CARD 11 Inhibitors
The CARD 11 inhibitors encompass a diverse group of compounds that exert their inhibitory effects through distinct mechanisms, targeting various nodes within interconnected signaling pathways. These pathways are intricately linked to the regulation of CARD 11 and its downstream signaling, particularly involving NF-κB activation. Firstly, BAY 11-7082 stands out as a potent inhibitor by targeting the IKK complex, preventing IκB phosphorylation and degradation. This disruption impedes the canonical NF-κB pathway, indirectly influencing CARD 11, which relies on NF-κB signaling for activation. Calmidazolium, another member of this class, interferes with CaMKII, disrupting calcium-dependent regulatory mechanisms that influence CARD 11 activation. Moreover, compounds like Curcumin and Quinacrine modulate CARD 11 indirectly by targeting upstream elements, such as IKK and the PI3K/Akt pathway, respectively.
The MAPK pathway is a central player in CARD 11 signaling, and inhibitors like JNK Inhibitor II, SB-203580, SP600125, and U0126 demonstrate their efficacy by disrupting this pathway. They indirectly modulate CARD 11 by interfering with MAPK-dependent signaling events critical for CARD 11 activation. Additionally, compounds like PI-103, Rapamycin, and Wortmannin target the PI3K/Akt/mTOR pathway, impacting CARD 11 signaling at multiple levels. Furthermore, the JAK/STAT pathway is implicated in CARD 11 activation, as exemplified by TG101209 inhibiting JAK2. This compound disrupts the pathway leading to CARD 11 activation and downstream NF-κB signaling. In summary, the CARD 11 inhibitors form a sophisticated class of chemicals that intricately manipulate interconnected signaling pathways to modulate CARD 11 activity indirectly. This diverse set of compounds showcases the complexity of designing inhibitors capable of finely tuning the CARD 11-mediated signaling cascade.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation by preventing IκB phosphorylation and degradation, indirectly modulating CARD 11, as it is a crucial upstream regulator of NF-κB signaling. This compound specifically disrupts the canonical NF-κB pathway by targeting the IKK complex, resulting in the inhibition of CARD 11-mediated activation of NF-κB. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $153.00 $600.00 | 27 | |
Calmidazolium inhibits calcium/calmodulin-dependent protein kinase II (CaMKII), affecting downstream pathways. CARD 11 activation is linked to CaMKII activity, and the inhibition of CaMKII by Calmidazolium indirectly suppresses CARD 11-mediated signaling by disrupting its calcium-dependent regulatory mechanisms. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin inhibits the NF-κB pathway by suppressing IKK activity. Through this mechanism, Curcumin indirectly modulates CARD 11, as it interferes with the upstream signaling cascades that lead to CARD 11 activation, particularly those involving IKK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK Inhibitor II (SP600125) targets the c-Jun N-terminal kinases (JNKs), which are implicated in CARD 11 signaling. By inhibiting JNK, this compound disrupts the MAPK pathway and interferes with downstream events, indirectly influencing CARD 11 activation and its associated pathways. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a dual PI3K/mTOR inhibitor that impacts the PI3K/Akt pathway. It indirectly modulates CARD 11 by interfering with the PI3K-dependent signaling events that contribute to CARD 11 activation and downstream NF-κB signaling. | ||||||
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $45.00 $56.00 $85.00 $3193.00 $4726.00 | 4 | |
Quinacrine inhibits IKKα/β, suppressing the NF-κB pathway. By targeting IKK, Quinacrine indirectly influences CARD 11, as IKK is an essential regulator upstream of CARD 11 in the NF-κB signaling cascade. This compound disrupts the pathway leading to CARD 11 activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, impacting the PI3K/Akt/mTOR pathway. This compound indirectly modulates CARD 11 by interfering with the mTOR-dependent signaling events that contribute to CARD 11 activation and downstream NF-κB signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB-203580 is a p38 MAPK inhibitor, influencing the MAPK pathway. Through this mechanism, SB-203580 indirectly modulates CARD 11, as it disrupts the p38 MAPK-dependent signaling events that contribute to CARD 11 activation and downstream NF-κB signaling. | ||||||
TG101209 | 936091-14-4 | sc-364731 sc-364731A | 5 mg 50 mg | $255.00 $1455.00 | ||
TG101209 inhibits JAK2, affecting the JAK/STAT pathway. This compound indirectly modulates CARD 11, as JAK2 is implicated in the activation of NF-κB through CARD 11 signaling. The inhibition of JAK2 disrupts the pathway leading to CARD 11 activation and downstream NF-κB signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits PI3K, affecting the PI3K/Akt pathway. This compound indirectly modulates CARD 11 by disrupting the PI3K-dependent signaling events that contribute to CARD 11 activation and downstream NF-κB signaling. | ||||||